A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia	B-cell chronic lymphocytic leukemia, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm	Active, not recruiting	Phase 2	2026-07-21		NCT02251548

4 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Blood Cancer Research Partnership	2
Dana-Farber Cancer Institute	324
Pharmacyclics LLC.	12
The Leukemia and Lymphoma Society	22

9 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Beth Israel Deaconess Medical Center	Boston	United States	462
Dana Farber Cancer Institute	Boston	United States	300
Duke University Medical Center	Durham	United States	505
Massachusetts General Hospital	Boston	United States	1015
University of Kansas Cancer Center	Westwood	United States	36
University of Miami Sylvester Comprehensive Cancer Center	Deerfield Beach	United States	2
University of Miami Sylvester Comprehensive Cancer Center	Coral Gables	United States	1
Unversity of Miami Sylvester Comprehensve Cancer Center	Miami	United States	1
West Michigan Cancer Center	Kalamazoo	United States	236